+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Oncology Drugs Market Report and Forecast 2023-2031

  • PDF Icon

    Report

  • 160 Pages
  • May 2023
  • Region: Global
  • Expert Market Research
  • ID: 5797836
Description Jump to:
The global oncology drugs market value was USD 156.7 billion in 2022, driven by the prevalence of cancer continues to rise across the globe. The market size is anticipated to grow at a CAGR of 7.3% during the forecast period of 2023-2031 to achieve a value of USD 295.5 billion by 2031.

Oncology Drugs: Introduction

Cancer, a group of diseases characterized by the uncontrolled growth and spread of abnormal cells, continues to be a leading cause of morbidity and mortality worldwide. The global oncology drugs market plays a critical role in addressing this challenge by providing a wide range of treatment options, including chemotherapy, targeted therapy, immunotherapy, and hormone therapy, among others. These drugs are designed to combat cancer by inhibiting cell growth, inducing apoptosis, or modulating the immune response to target cancer cells more effectively.

Oncology Drugs Market Scenario

The adoption of oncology drugs has been increasing steadily as the prevalence of cancer continues to rise, and advancements in cancer research leading to the development of novel therapies. The increasing focus on personalized medicine and targeted therapies has further fueled the growth of the market, as these treatments often offer improved efficacy and fewer side effects compared to traditional chemotherapy.

In recent years, the global oncology drugs market has witnessed significant growth, driven by factors such as the increasing prevalence of cancer, advancements in cancer research, the development of novel treatment modalities, and a growing focus on personalized medicine. The market is also fueled by the rising demand for innovative therapies, which offer improved efficacy, fewer side effects, and better patient outcomes compared to traditional treatments.

North America: The largest market for oncology drugs, driven by factors such as high cancer incidence, advanced healthcare infrastructure, and a strong focus on research and development in the field of oncology.

Europe: The second-largest market, with increasing demand for innovative cancer therapies and a growing emphasis on personalized medicine and targeted treatments.

Asia-Pacific: Expected to witness the highest growth rate due to factors such as rising cancer prevalence, increasing healthcare expenditure, and growing awareness of novel oncology treatments.

Oncology Drugs Market Segmentations

Market Breakup by Drug Class

Chemotherapy

  • Alkylating Agents
  • Antimetabolites
  • Others

Targeted Therapy

  • Monoclonal Antibodies
  • Others
  • Immunotherapy
  • Hormonal Therapy
  • Others

Market Breakup by Indications

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Liver Cancer
  • Esophageal Cancer
  • Cervical Cancer
  • Kidney Cancer
  • Bladder Cancer
  • Breast Cancer
  • Others

Market Breakup by Route of Administration

Oral

  • Tablets
  • Capsules

Parenteral

  • Intravascular
  • intramuscular
  • Others

Market Breakup by End User

  • Hospitals
  • Clinics
  • Specialty Centers
  • Research Institutes
  • Others

Market Breakup by Distribution Channels

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others

Market Breakup by Region

North America

  • United States of America
  • Canada

Europe

  • United Kingdom
  • Germany
  • France
  • Italy
  • Others

Asia Pacific

  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • Others

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Others

Middle East and Africa

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Key Trends in the Oncology Drugs Market

  • Targeted therapies and immunotherapies: These novel treatment approaches are revolutionizing cancer treatment by offering more effective and precise options for various cancer types
  • Personalized medicine and biomarker-driven therapies: Advances in genomics and molecular biology have enabled the development of therapies tailored to individual patients, based on their unique genetic profiles and tumor characteristics
  • Growing pipeline of innovative drugs: The oncology drugs market is benefiting from a robust pipeline of new therapies in various stages of development, offering the potential for significant breakthroughs in cancer treatment
  • Expansion of indications for approved drugs: Pharmaceutical companies are increasingly seeking to expand the approved indications for existing oncology drugs, thereby increasing their market potential
  • Strategic collaborations and mergers: Collaborations, mergers, and acquisitions between pharmaceutical companies, biotechnology firms, and research institutions are driving innovation and fostering the development of new cancer therapies
Oncology Drugs Market: Competitor Analysis
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
  • F. Hoffmann-La Roche Ltd
  • Mylan N.V
  • Teva Pharmaceutical Industries Ltd
  • Sanofi
  • Pfizer Inc
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co., Inc
  • Allergan
  • AstraZeneca
  • AbbVie Inc
  • Johnson & Johnson Private Limited
  • Cipla Inc
  • Abbott
  • Merck KGaA
  • LEO Pharma A/S
  • Bausch Health Companies Inc
  • Sun Pharmaceutical Industries Ltd
  • Aurobindo Pharma
  • Lupin
  • Hikma Pharmaceuticals PLC
  • Fresenius Kabi AG
  • Amneal Pharmaceuticals LLC.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Cancer Epidemiology Analysis
5.1 Epidemiology Overview (2016-2031)
5.2 North America Cancer Epidemiology (2016-2031)
5.3 Europe Cancer Epidemiology (2016-2031)
5.4 Asia-Pacific Cancer Epidemiology (2016-2031)
5.5 Latin America Cancer Epidemiology (2016-2031)
5.6 Middle East & Africa Cancer Epidemiology (2016-2031)
6 Global Oncology Drugs Market Overview
6.1 Global Oncology Drugs Market Historical Value (2016-2022)
6.2 Global Oncology Drugs Market Forecast Value (2023-2031)
7 Global Oncology Drugs Market Landscape
7.1 Global Oncology Drugs Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Global Oncology Drugs Product Landscape
7.2.1 Analysis by Drug Class
7.2.2 Analysis by End User
7.2.3 Analysis by Indication
8 Oncology Drug Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Global Oncology Drugs Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Global Oncology Drugs Market Segmentation
11.1 Global Oncology Drugs Market by Drug Class
11.1.1 Market Overview
11.1.2 Chemotherapy
11.1.2.1 Alkylating Agents
11.1.2.2 Antimetabolites
11.1.2.3 Others
11.1.3 Targeted Therapy
11.1.3.1 Monoclonal Antibodies
11.1.3.2 Others
11.1.4 Immunotherapy
11.1.5 Hormonal Therapy
11.1.6 Others
11.2 Global Oncology Drugs Market by Indications
11.2.1 Market Overview
11.2.2 Lung Cancer
11.2.3 Stomach Cancer
11.2.4 Colorectal Cancer
11.2.5 Breast Cancer
11.2.6 Prostate Cancer
11.2.7 Liver Cancer
11.2.8 Esophageal Cancer
11.2.9 Cervical Cancer
11.2.10 Kidney Cancer
11.2.11 Bladder Cancer
11.2.12 Others
11.3 Global Oncology Drugs Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.2.1 Tablets
11.3.2.2 Capsules
11.3.3 Parenteral
11.3.3.1 Intravascular
11.3.3.2 intramuscular
11.3.4 Others
11.4 Global Oncology Drugs Market by End User
11.4.1 Market Overview
11.4.2 Hospitals
11.4.3 Clinics
11.4.4 Specialty Centers
11.4.5 Research Institutes
11.4.6 Others
11.5 Global Oncology Drugs Market by Distribution Channels
11.5.1 Market Overview
11.5.2 Hospitals Pharmacies
11.5.3 Retail Pharmacies
11.5.4 Online Pharmacies
11.5.5 Others
11.6 Global Oncology Drugs Market by Region
11.6.1 Market Overview
11.6.2 North America
11.6.3 Europe
11.6.4 Asia Pacific
11.6.5 Latin America
11.6.6 Middle East and Africa
12 North America Oncology Drugs Market
12.1 Market Share by Country
12.2 United States of America
12.3 Canada
13 Europe Oncology Drugs Market
13.1 Market Share by Country
13.2 United Kingdom
13.3 Germany
13.4 France
13.5 Italy
13.6 Others
14 Asia Pacific Oncology Drugs Market
14.1 Market Share by Country
14.2 China
14.3 Japan
14.4 India
14.5 ASEAN
14.6 Australia
14.7 Others
15 Latin America Oncology Drugs Market
15.1 Market Share by Country
15.2 Brazil
15.3 Argentina
15.4 Mexico
15.5 Others
16 Middle East and Africa Oncology Drugs Market
16.1 Market Share by Country
16.2 Saudi Arabia
16.3 United Arab Emirates
16.4 Nigeria
16.5 South Africa
16.6 Others
17 Patent Analysis
17.1 Analysis by Type of Patent
17.2 Analysis by Publication year
17.3 Analysis by Issuing Authority
17.4 Analysis by Patent Age
17.5 Analysis by CPC Analysis
17.6 Analysis by Patent Valuation
17.7 Analysis by Key Players
18 Grants Analysis
18.1 Analysis by year
18.2 Analysis by Amount Awarded
18.3 Analysis by Issuing Authority
18.4 Analysis by Grant Application
18.5 Analysis by Funding Institute
18.6 Analysis by NIH Departments
18.7 Analysis by Recipient Organization
19 Clinical Trials Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Funding Analysis
20.1 Analysis by Funding Instances
20.2 Analysis by Type of Funding
20.3 Analysis by Funding Amount
20.4 Analysis by Leading Players
20.5 Analysis by Leading Investors
20.6 Analysis by Geography
21 Partnership and Collaborations Analysis
21.1 Analysis by Partnership Instances
21.2 Analysis by Type of Partnership
21.3 Analysis by Leading Players
21.4 Analysis by Geography
22 Regulatory Framework
22.1 Regulatory Overview
22.1.1 US FDA
22.1.2 EU EMA
22.1.3 INDIA CDSCO
22.1.4 JAPAN PMDA
22.1.5 Others
23 Supplier Landscape
23.1 F. Hoffmann-La Roche Ltd.
23.1.1 Financial Analysis
23.1.2 Product Portfolio
23.1.3 Demographic Reach and Achievements
23.1.4 Mergers and Acquisitions
23.1.5 Certifications
23.2 Mylan N.V.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Mergers and Acquisitions
23.2.5 Certifications
23.3 Teva Pharmaceutical Industries Ltd.
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Mergers and Acquisitions
23.3.5 Certifications
23.4 Sanofi
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Mergers and Acquisitions
23.4.5 Certifications
23.5 Pfizer Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Mergers and Acquisitions
23.5.5 Certifications
23.6 GlaxoSmithKline plc
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Mergers and Acquisitions
23.6.5 Certifications
23.7 Novartis AG
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Mergers and Acquisitions
23.7.5 Certifications
23.8 Bayer AG
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Mergers and Acquisitions
23.8.5 Certifications
23.9 Eli Lilly and Company
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Mergers and Acquisitions
23.9.5 Certifications
23.10 Merck & Co., Inc.
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Mergers and Acquisitions
23.10.5 Certifications
23.11 Allergan
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Mergers and Acquisitions
23.11.5 Certifications
23.12 AstraZeneca
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Mergers and Acquisitions
23.12.5 Certifications
23.13 AbbVie Inc.
23.13.1 Financial Analysis
23.13.2 Product Portfolio
23.13.3 Demographic Reach and Achievements
23.13.4 Mergers and Acquisitions
23.13.5 Certifications
23.14 Johnson & Johnson Private Limited
23.14.1 Financial Analysis
23.14.2 Product Portfolio
23.14.3 Demographic Reach and Achievements
23.14.4 Mergers and Acquisitions
23.14.5 Certifications
23.15 Cipla Inc.
23.15.1 Financial Analysis
23.15.2 Product Portfolio
23.15.3 Demographic Reach and Achievements
23.15.4 Mergers and Acquisitions
23.15.5 Certifications
23.16 Abbott
23.16.1 Financial Analysis
23.16.2 Product Portfolio
23.16.3 Demographic Reach and Achievements
23.16.4 Mergers and Acquisitions
23.16.5 Certifications
23.17 Merck KGaA
23.17.1 Financial Analysis
23.17.2 Product Portfolio
23.17.3 Demographic Reach and Achievements
23.17.4 Mergers and Acquisitions
23.17.5 Certifications
23.18 LEO Pharma A/S
23.18.1 Financial Analysis
23.18.2 Product Portfolio
23.18.3 Demographic Reach and Achievements
23.18.4 Mergers and Acquisitions
23.18.5 Certifications
23.19 Bausch Health Companies Inc.
23.19.1 Financial Analysis
23.19.2 Product Portfolio
23.19.3 Demographic Reach and Achievements
23.19.4 Mergers and Acquisitions
23.19.5 Certifications
23.20 Sun Pharmaceutical Industries Ltd.
23.20.1 Financial Analysis
23.20.2 Product Portfolio
23.20.3 Demographic Reach and Achievements
23.20.4 Mergers and Acquisitions
23.20.5 Certifications
23.21 Aurobindo Pharma
23.21.1 Financial Analysis
23.21.2 Product Portfolio
23.21.3 Demographic Reach and Achievements
23.21.4 Mergers and Acquisitions
23.21.5 Certifications
23.22 Lupin
23.22.1 Financial Analysis
23.22.2 Product Portfolio
23.22.3 Demographic Reach and Achievements
23.22.4 Mergers and Acquisitions
23.22.5 Certifications
23.23 Hikma Pharmaceuticals PLC
23.23.1 Financial Analysis
23.23.2 Product Portfolio
23.23.3 Demographic Reach and Achievements
23.23.4 Mergers and Acquisitions
23.23.5 Certifications
23.24 Fresenius Kabi AG
23.24.1 Financial Analysis
23.24.2 Product Portfolio
23.24.3 Demographic Reach and Achievements
23.24.4 Mergers and Acquisitions
23.24.5 Certifications
23.25 Amneal Pharmaceuticals LLC.
23.25.1 Financial Analysis
23.25.2 Product Portfolio
23.25.3 Demographic Reach and Achievements
23.25.4 Mergers and Acquisitions
23.25.5 Certifications
24 Global Oncology Drugs Market-Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Company Competitiveness Analysis (Additional Insight)
26.1 Very Small Companies
26.2 Small Companies
26.3 Mid-Sized Companies
26.4 Large Companies
26.5 Very Large Companies
27 Payment Methods (Additional Insight)
27.1 Government Funded
27.2 Private Insurance
27.3 Out-of-Pocket

Companies Mentioned

  • F. Hoffmann-La Roche Ltd.
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Bayer AG
  • Eli Lilly and Company
  • Merck & Co. Inc.
  • Allergan
  • Astrazeneca
  • Abbvie Inc.
  • Johnson & Johnson Private Limited
  • Cipla Inc.
  • Abbott
  • Merck Kgaa
  • Leo Pharma A/S
  • Bausch Health Companies Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Aurobindo Pharma
  • Lupin
  • Hikma Pharmaceuticals plc
  • Fresenius Kabi AG
  • Amneal Pharmaceuticals LLC.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages160
PublishedMay 2023
Forecast Period2023 - 2031
Estimated Market Value ( USD ) in 2023 $ 168.2 Billion
Forecasted Market Value ( USD ) by 2031 $ 295.5 Billion
Compound Annual Growth Rate7.3%
Regions CoveredGlobal
No. of Companies Mentioned25

Related Topics

Related Reports

Oncology Drugs Market by Indication, Drug Class, Route of Administration, Distribution, End-use - Global Forecast 2025-2030 - Product Image

Oncology Drugs Market by Indication, Drug Class, Route of Administration, Distribution, End-use - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
United States Cancer Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032 - Product Image

United States Cancer Drugs Market: Prospects, Trends Analysis, Market Size and Forecasts up to 2032

  • Report
  • 80 Pages
  • United States
From
North America Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023 - 2030 - Product Image

North America Oncology Drugs Market Size, Share & Industry Trends Analysis Report By Indication, By Drug Class Type (Targeted Therapy, Immunotherapy (Biologic Therapy), Chemotherapy and Hormonal Therapy), By Country and Growth Forecast, 2023 - 2030

  • Report
  • 151 Pages
  • North America
From
Chemotherapy Induced Neutropenia Market Report and Forecast 2024-2032 - Product Image

Chemotherapy Induced Neutropenia Market Report and Forecast 2024-2032

  • Report
  • 140 Pages
  • Global
From
Immune Checkpoint Inhibitors Market Report and Forecast 2024-2032 - Product Image

Immune Checkpoint Inhibitors Market Report and Forecast 2024-2032

  • Report
  • 140 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.